We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Phoenix CPO Test Evaluated for Detection of Carbapenemase Producers

By LabMedica International staff writers
Posted on 14 Nov 2019
Print article
Image: The BD Phoenix CPO detect test will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs) (Photo courtesy of Becton-Dickinson).
Image: The BD Phoenix CPO detect test will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs) (Photo courtesy of Becton-Dickinson).
The use of nucleic acid amplification tests (NAAT) to identify rapidly Carbapenemase-Producing Organisms (CPO) from samples such as positive blood culture and stools is an alternative approach to establish rapidly an optimal empirical antibiotic therapy or for infectious control management.

Most carbapenemase NAAT panels detect the most frequent gene variants encoding for carbapenemases including KPC, NDM, OXA-48, VIM and IMP. However, these tests cannot exclude the presence of a gene encoding another carbapenemase type and are relatively expensive, hence preventing their use to screen systematically some specimen types or bacterial isolates with CPO suspicion, especially in low to very low prevalence countries.

Medical microbiologists at the Lausanne University Hospital (Lausanne, Switzerland) tested the performance of the Phoenix CPO Detect Test (Becton-Dickinson, Franklin Lakes, NJ, USA) on a collection of 92 molecularly-characterized CPO and 93 non-CPO. The collection included 27 non-fermentative bacteria and 158 Enterobacterales. In addition, 295 clinical isolates, including 135 isolates with suspected carbapenemase, were prospectively, but not consecutively isolated from various de-identified clinical specimens during a 10 months period ranging from January to October 2018.

MALDI-TOF was used as an additional phenotypic test to exclude the presence of carbapenemase activity in Phoenix CPO Detect test false positives. All false positive results of the Phoenix CPO Detect test from the prospective study were verified by NAAT testing using the BD MAX Check-Points CPO test. Whole genome sequencing and analysis with libraries prepared with the Nextera XT kit (Illumina, San Diego, USA).

In a retrospective study the scientists reported the Phoenix CPO test exhibited 92.4% accuracy, 97.8% sensitivity 87.1% specificity for carbapenemase detection. The Phoenix CPO test provided a classification to class A, B, and D for 81.3% of detected carbapenemases with 94.6% accuracy. In a prospective study, the CPO test detection performance showed 77.8% accuracy, 100% sensitivity and 67.8% specificity on 135 CPO suspicious isolates and 98.8% accuracy and specificity on 160 non-CPO suspicious isolates. Compared to routine testing, the implementation of the CPO test allowed a mean reduction of 21.3 hours in turnaround time (TAT), 16.8 minutes) in hands-on time (HOT), and CHF 20.6 in costs.

The authors concluded that the Phoenix CPO Detect test likely represents a new diagnostic tool with added value for the detection and management of CPO infection and colonization. The CPO test is reliable for the detection of CPO with a high sensitivity but the relatively low specificity requires the use of additional confirmatory methods. The carbapenemase classification accuracy is robust to provide preliminary results before molecular characterization. The study was published on October 18, 2019 in the journal Clinical Microbiology and Infection.

Related Links:
Lausanne University Hospital
Becton-Dickinson
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.